← Compound index
COMPOUND RECORD / DSIP

DSIPДельта-сон-индуцирующий пептид

Delta sleep-inducing peptide (DSIP) is a nine-amino-acid peptide, Trp–Ala–Gly–Gly–Asp–Ala–Ser–Gly–Glu. Its name comes from early sleep experiments. Later studies examined sleep, pain and withdrawal.

SleepStress
Source linked

What the studies found

Controlled study in people · 1992

Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.

Objective sleep
Higher efficiency and shorter latency, described as weak effectsAuthors note possible contribution from incidental placebo-group changes
Subjective sleep quality
No changeNo numerical sleep-minute difference in the abstract

In 16 chronic-insomnia patients, DSIP produced weak objective sleep differences and no consistent subjective sleep benefit; the authors found little likely therapeutic value.

Study notes · methods, sources and limitations

Participants or model 16 patients; double-blind matched-pairs parallel groups

Design Double-blind matched-pairs parallel comparison: 8 DSIP, 8 glucose placebo; five laboratory nights.

Participants
8 DSIP; 8 placebo
Studied schedule
25 nmol/kg IV before nights 3, 4 and 5

Important limitations

  • Small, brief study; selected statistically significant endpoints do not establish a meaningful overall benefit.
  • Design figures are available; objective effect sizes in minutes and confidence intervals are not. The original authors did not infer a major therapeutic benefit.

Neuropsychobiology 26(4):193-197 · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Animal research · 2014

Deltaran maternal-exposure abstract reports 96% offspring survival

Study of multiple preparations

Reported survival
Deltaran 96%; Pinealon 94%No n, uncertainty, untreated-hypoxia rate or numerical Cortexin survival supplied
Caspase-3 conflict
Deltaran+hypoxia is described as +144% in cortex and +109% in brainstem, then as remaining at control levelBoth statements occur in the same abstract; do not resolve by assumptionFirst sentence: p<0.0001 and p<0.001, respectively

Deltaran, a DSIP-containing preparation with glycine, had 96% reported offspring survival in the 2014 conference abstract. Group sizes and an untreated-hypoxia survival rate are missing; the biochemical result is internally contradictory.

Study notes · methods, sources and limitations

Participants or model 21-day-old outbred rat offspring; seven listed treatment groups; no group sizes supplied

Design Maternal intraperitoneal exposure throughout pregnancy. Daily hypobaric hypoxia on gestation days 13–20, 66.41 kPa for three hours. Offspring Morris maze and cortical/brainstem caspase-3 at day 21.

Important limitations

  • Formulation-level animal findings cannot be assigned to isolated DSIP or treated as human pregnancy-safety evidence.
  • Conference abstract with missing denominators and an internally inconsistent biochemical result; not a clinical trial. Deltaran is a DSIP-containing formulation with glycine; results are not proof for isolated DSIP. Formulation mass versus active-peptide mass is not resolved by this abstract. Shared Rostov authors and models may overlap the 2012 papers and dissertations; no pooled sample or independent-replication count is calculated.

X International Congress “Neuroscience for Medicine and Psychology”, Sudak, 2–12 June 2014, pp.233–234 · Conference abstract

Original source or citation ↗

Study results and tables ↗

Animal research · 1999

DSIP across hypoxia, swimming, immobilization and audiogenic stress

Monoamine time course
Selected changes observed for up to 5 days after an injectionMeasurements of brain neurochemistry; not drug exposure or human duration of action.
Forced swimming
Longer time before fatigue describedNo verified numerical swim-time contrast in accessible conclusions.
Other stress models
Changes in leukocyte pattern, lipid peroxidation and membrane measuresHypoxia, restricted movement and audiogenic stress; distinct experiments.

The author describes brain monoamine changes observed up to five days after a DSIP injection and delayed fatigue in forced swimming.

Study notes · methods, sources and limitations

Participants or model Animal experiments in multiple stress models; group counts not verified in accessible text

Design Animal experiments in multiple stress models; group counts not verified in accessible text

Important limitations

  • Five days refers to observation of selected biochemical changes, not measured half-life or five days of benefit.
  • Five days refers to observation of selected biochemical changes, not measured half-life or five days of benefit. Swimming time and survival magnitudes and adverse effects require full results tables.
  • An archival stress-response hypothesis. Exact effects and dose schedules remain unresolved.

Rostov-on-Don doctoral dissertation, 338 pp. · Dissertation

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About DSIP

Names in this research collection

Delta sleep-inducing peptide · Delta-sleep inducing peptide · WAGGDASGE

Identity / background source ↗

Research background

A peptide first characterized in Swiss sleep research and later studied in Soviet/Russian analogue and stress-adaptation programs. Ordinary DSIP, modified analogues and piracetam combinations have distinct evidence.

Pregnancy and offspring research

Deltaran, a DSIP-containing preparation with glycine, had 96% reported offspring survival in the 2014 conference abstract. Group sizes and an untreated-hypoxia survival rate are missing; the biochemical result is internally contradictory.

Formulation-level animal findings cannot be assigned to isolated DSIP or treated as human pregnancy-safety evidence.

Reported findings and methods ↗ · Pregnancy research: full evidence review and archive ↗

More study findings

Animal research · 2006

Deltaran and avoidance learning in animals

Study of multiple preparations

Conditioned swimming avoidance
Acquisition and retention changedThe original abstract gives no numerical effect or group size.
Spontaneous behavior
More horizontal and vertical movement and less time freezingDirection only from the original abstract. Swimming was an avoidance task.

The abstract reports changes in acquisition and retention of an active swimming-avoidance response, more spontaneous movement and less freezing with Deltaran.

Study notes · methods, sources and limitations

Participants or model Laboratory animals in conditioned avoidance and locomotor behavior experiments. Group sizes unverified.

Design Laboratory animals in conditioned avoidance and locomotor behavior experiments. Group sizes unverified.

Important limitations

  • Deltaran contains DSIP and glycine. The contribution of isolated DSIP was not established. Original dose, groups and numerical outcomes remain unverified.
  • An animal learning and behavior experiment. Its abstract supplies no athletic endurance endpoint.

Medline.ru. 7:47–54, article 5 · Medline.ru. 7:47–54, article 5

Original source or citation ↗

Study results and tables ↗

Animal research · 2017

Deltaran and plasma superoxide dismutase in rats

Study of multiple preparations

Plasma superoxide dismutase activity
+28.6% in males and +21.1% in femalesVersus corresponding controls.p<0.05 as reported
Plasma protein and total lipids
Protein +14.8% in males and total lipids +20.2% in femalesVersus corresponding controls. The reverse sex-specific comparisons showed no reported difference.p<0.05 as reported
Female plasma phospholipid share
−21.3%Share of plasma lipids, a separate measure from total lipids.

Plasma superoxide dismutase activity increased 28.6% in male rats and 21.1% in females compared with controls.

Study notes · methods, sources and limitations

Participants or model Male and female laboratory rats. The abstract prints n=6 per group.

Design Male and female rats received intranasal Deltaran for five days and were compared with controls. The abstract reports six per group and measures plasma protein, lipids and antioxidant enzyme activity.

Important limitations

  • Small conference experiment and an unusually high printed formulation dose. No performance, endurance or human endpoint was measured.
  • These biomarker changes describe the tested DSIP-plus-glycine formulation.

Reviews of Clinical Pharmacology and Drug Therapy. 15(Suppl. 2):21–22 · Reviews of Clinical Pharmacology and Drug Therapy. 15(Suppl. 2):21–22

Original source or citation ↗

Study results and tables ↗

Animal research · 2006

Age and baseline anxiety in Lysenko’s peptide stress models

Study of multiple preparations

High-anxiety young rats
Vilon and GVS-111 were highlighted in the author’s conclusionsOriginal group-level numerical estimates and doses still need retrieval.
Stress-response direction
Favorable and unfavorable responses describedThe author discusses this for GVS-111 and an experimental preparation called NKT. NKT identity remains unresolved.

The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.

Study notes · methods, sources and limitations

Participants or model Rats grouped by age and baseline anxiety; series-specific denominators remain unverified.

Design Hypokinesia, hypoxia and exertion models, with behavioral, immune and oxidative endpoints. Twenty-four-hour hypokinesia was one stress protocol.

Important limitations

  • Potential overlap with narrower author-network dissertations, including Morgul and Rudenko. Outcomes cannot be pooled or assigned to humans.
  • A mechanistic program on stress response. The dissertation-level conclusion does not isolate all preparation-specific effects.

Doctoral dissertation, 244 pp., introduction and conclusions · Doctoral dissertation, 244 pp., introduction and conclusions

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2008

Climatic chamber workload by condition

Study of multiple preparations

Deltaran · cold (n=18)
196 → 217 WSeparate comparison. The author reports a significant increase from the pre-chamber measure.

Reported cycling work capacity in healthy men aged 20–24.

Study notes · methods, sources and limitations

Participants or model 301 men aged 20–24 across the full program. Selected tables compare 17 Cortexin, 18 Noopept, 17 Cerebrolysin and nine placebo participants, with historical controls in cold.

Design Tabai climatic chamber: −10°C with 2.5 m/s airflow, +45°C at 80% humidity, or 3,000 m simulated altitude. The abstract specifies 40 minutes for cold and heat and 90 minutes at altitude within a longer chamber session.

Important limitations

  • Related reports have overlapping results and group differences before exposure.
  • Pre-chamber values reflect the testing protocol and are not established drug-free baselines. Small groups and multiple outcomes limit interpretation. Related 2007 journal and conference reports share investigators, treatments and chamber conditions. Matching workload means indicate overlap.
  • The ledger uses the 301-person dissertation total once for these related reports.

Development and Study of New Meteoadaptogens, Kirov Military Medical Academy doctoral author abstract · Original dissertation author abstract

Original source or citation ↗

Study results and tables ↗

Animal research · 2009

Rat behavioral assays: DSIP-containing Deltaran

Study of multiple preparations

Deltaran · grooming
Grooming reactions increasedThe report tested Deltaran, a DSIP-containing formulation; this observation is not assigned to isolated DSIP.

Separate comparisons in an assay battery.

Study notes · methods, sources and limitations

Participants or model 192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery

Design 192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery

Reported study exposure
0.1 mg/kg intraperitoneally in the rat study.

Important limitations

  • Deltaran was tested as a formulation. This is not a result for isolated DSIP.
  • Multiple behavioral comparisons, endpoint-specific group sizes and precise uncertainties need table recovery. Deltaran is the tested DSIP-containing formulation; no result for isolated DSIP can be inferred. The 2015 dissertation used separate doses/routes; it is not confirmed as independent replication of every experiment.
  • Opposing effects across assays are informative. Electrical self-stimulation and immobility are behavior readouts, and neither establishes improved human motivation or endurance.

Medical Academic Journal, 2009; publisher article 9357 · Original journal article

Original source or citation ↗

Study results and tables ↗

Animal research · 2004

DSIP analogues ID-1, ID-3 and ID-8 in age-stratified rat stress models

Study of multiple preparations

Analogue identities
ID-1, ID-3 and ID-8 tested separately from parent DSIP and piracetamAnalogue codes are reported; sequence-level identity was not independently resolved.
Age and oxidative response
ID-3 and piracetam were highlighted in old rats, including slower MDA formationQualitative conclusions only; no verified magnitude.
Other endpoints
Leukocyte profile and chromosomal-aberration outcomes varied by analogue and ageRestricted-movement model; biochemical and cytogenetic effects rather than sport performance.

The dissertation describes analogue- and age-dependent changes in leukocytes, oxidative markers and chromosome damage. ID-3 and piracetam were highlighted in older rats.

Study notes · methods, sources and limitations

Participants or model Rats of different ages under intact and restricted-movement conditions; DSIP and piracetam served as distinct comparators

Design Rats of different ages under intact and restricted-movement conditions; DSIP and piracetam served as distinct comparators

Important limitations

  • Sequence identities, exact comparative estimates and doses need original table recovery.
  • Sequence identities, exact comparative estimates and doses need original table recovery. The activity of these analogues does not establish an effect of DSIP itself or efficacy in humans.
  • The primary value is a lead for analogue-specific research; the parent peptide and analogues remain distinct.

Candidate dissertation, 152 pp.; Makhachkala author abstract, 22 pp. · Dissertation

Original source or citation ↗

Study results and tables ↗

Controlled study in people · 1987

Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.

Sleep and daytime performance
Reported improvements; numerical changes not suppliedSleep effects reportedly persisted on the first placebo post-treatment night

A 14-person placebo-controlled insomnia report described improved sleep and daytime performance over seven nights of DSIP, without giving numerical sleep or performance effect sizes in its abstract.

Study notes · methods, sources and limitations

Participants or model 14 middle-aged patients with chronic insomnia

Design 14 middle-aged chronic insomniacs; double-blind placebo-controlled administration and polysomnography.

Participants
14 chronic-insomnia patients
Observation schedule
7 successive treatment nights; daytime testing before and after 6 injections

Important limitations

  • Small sample and short follow-up; allocation and complete methods require appraisal.
  • This positive report is shown alongside the separate weak/neutral DSIP comparisons; their findings should not be pooled without full methods.

European neurology 27(2):120-129 · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Controlled study in people · 1987

Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs.

Awakenings and wake time
Decreased during DSIP, without significant baseline or placebo differencesAlso applies to NREM latency and waking after sleep onset
NREM and stage 2 sleep
Nominal differences versus placebo, with the same differences already present at baseline
Slow-wave and REM sleep
Not modified

A double-blind crossover study found little clinically significant sleep improvement with DSIP; some nominal sleep-stage differences were already present at baseline.

Study notes · methods, sources and limitations

Participants or model Patients with chronic insomnia; double-blind crossover

Design Insomnia patients studied over four nights with polysomnography; sample size not stated in the abstract.

Studied exposure
25 nmol/kg intravenously; four-night crossover

Important limitations

  • Baseline differences complicate interpretation; sample size is not provided in the indexed abstract.
  • The abstract contains no sleep-duration effect sizes or arm-level counts. Its conclusion is limited clinical significance.

International journal of clinical pharmacology research 7(2):105-110 · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Research updates ↗

Compound class
Experimental nonapeptide
Research collection
Neuropeptide research · editorial grouping
Institutions in linked studies
Neurocybernetics Institute, Rostov State University · Severtsov Institute of Ecology and Evolution, Russian Academy of Sciences
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Small insomnia studies with conflicting results; uncontrolled withdrawal report

Study methods

Short studies, baseline imbalances and incomplete full-text appraisal

Independent replication

Animal analogue results do not replicate ordinary DSIP efficacy; overlapping reports need checking

Source access

Indexed abstracts, original-paper repository and critical-review full text

Safety evidence

Long-term safety and safety of marketed preparations are not established by these records

Open a topic for the evidence assessment.

More findings, background and history
RELATED PEPTIDE RESEARCH / UPDATED OCTOBER 2026

Connections in the research

Historical extreme-state peptide research also includes Liberol and FMRFamide-related archival leads. Their effects and mixture experiments cannot be assigned to DSIP.

View the peptide family map and sources ↗

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗
DSIP / THREE RESEARCH BRANCHES

Sleep, peptide structure and stress adaptation.

The 1977 Schoenenberger–Monnier report anchors the Swiss discovery. Soviet and Russian investigators later studied modified peptides and stress-related metabolism. These are connected research histories, not interchangeable evidence for an ordinary DSIP product.

Original characterization ↗

1. Ordinary DSIP: mixed human sleep results

1987 · positive report

Schneider-Helmert’s small study reported improved sleep and daytime performance in 14 patients. It supplies a positive result, not definitive confirmation.

14-patient study ↗

1987 · little clinical significance

Monti and colleagues found that apparent stage-2 and NREM differences were already present at baseline. Slow-wave and REM sleep were unchanged.

Crossover study ↗

1992 · weak effects

In 16 patients, selected objective measures improved, but effects were weak and subjective sleep quality did not change. The authors judged substantial short-term benefit unlikely.

Matched-pairs study ↗

2. Modified DSIP analogues: structure changes the outcome

The 1986 rabbit and rat experiments tested chemically modified peptides. Full-length D-Trp¹ and D-Tyr¹ analogues could promote sleep while a shortened fragment produced different effects. The experiments tested DSIP analogues.

Rabbit experiment ↗ · Rat structure–activity study ↗ · Comparative report ↗

The 2001 comparison of 13 analogues

  • Ordinary DSIP and most analogues: no statistically significant sleep effect.
  • N-MeAla²-DSIP and Pro²-DSIP: increased slow-wave sleep.
  • β-Ala²-DSIP: suppressed sleep.

Peptides were administered into rabbit brain ventricles. The experimental route and modified structures prevent direct extrapolation to marketed injections or nasal products.

Original Russian record ↗

3. Rostov stress research and DSIP + piracetam

The 1995 combination study examined restricted movement and neurotransmitter amino-acid balance. The 1999 study examined membrane metabolism during hyperbaric oxygen exposure. Both are rat experiments; stronger combined effects in their abstracts do not establish formal synergy or human benefit.

1995 combination paper ↗ · 1999 hyperoxia paper ↗ · Combination matrix ↗ · Piracetam ↗

Hyperoxia is excess oxygen, not hypoxia. The oxygen-toxicity and seizure experiments do not establish protection from oxygen deprivation. Separate hypokinesia work investigated proteolytic enzymes and possible regulation of other peptides.

Oxygen-pressure experiment ↗ · Proteolysis study ↗

Identity and mechanism remain research questions

Kovalzon and Strekalova’s 2006 review questioned whether synthetic DSIP fully represented the endogenous material detected by antibody assays. DSIP-like immunoreactivity is not itself molecular identification. Their proposed endocrine explanation and receptor questions are historical hypotheses, not settled mechanisms.

Critical review ↗

Other clinical history

The early withdrawal report was uncontrolled and lost or excluded a substantial share of participants. It documents a research branch, not evidence supporting self-treatment.

1983 withdrawal report ↗

Full texts, translations and sources to locate

Repository-listed full text / PDF

1977 DSIP characterization — open full-text access

Same publication as dsip-265572. Indexed abstract checked; full experimental tables remain to be appraised.

Source details ↗
Translation and original source

Sleep-inducing properties of DSIP analogs: structural and functional relationships

The Russian record (PMID 11525128) describes the same experiment. Complete tables, uncertainty estimates and analogue-specific results are unavailable.

Source details ↗
Publisher full text; selected passages checked

DSIP: a still unresolved riddle — publisher full text

Access companion to dsip-16539679. Reports opposite effects of related dermorphin analogues and proposes an indirect hormonal explanation; this remains a hypothesis.

Source details ↗
Full methods unavailable

Rostov series and analogue experiments

Related sources include the 1995 and 1999 DSIP–piracetam papers, 1986 analogue reports and 2001 structure–activity tables. Group overlap, routes, controls and adverse effects require the full articles. The abstracts give no formal test of synergy.

Source details ↗
Educational only; not medical advice. Seek qualified healthcare help for sleep problems or any other condition. Long-term safety and the safety of marketed DSIP preparations are not established here. No personal dosing or combination recommendation is provided.

Explore the expanded peptide research collection and unresolved source trails ↗

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Animal research · 2006

Deltaran and avoidance learning in animals

The abstract reports changes in acquisition and retention of an active swimming-avoidance response, more spontaneous movement and less freezing with Deltaran.

Study notes and original source
2006Animal / experimentalRussian-language source

Deltaran and avoidance learning in animals

· Medline.ru. 7:47–54, article 5

Format: Original journal abstract. Full PDF tables unavailable. · Reviewed: Reported methods, results and evidence limitations

G. G. Dmitriev, E. Yu. Bonitenko, M. B. Ivanov, V. A. Basharin · Medline.ru. 7:47–54, article 5

The abstract reports changes in acquisition and retention of an active swimming-avoidance response, more spontaneous movement and less freezing with Deltaran.

Results and tables

Reported findings and study design

The abstract reports changes in acquisition and retention of an active swimming-avoidance response, more spontaneous movement and less freezing with Deltaran.

Laboratory animals in conditioned avoidance and locomotor behavior experiments. Group sizes unverified.

Population or model Laboratory animals in conditioned avoidance and locomotor behavior experiments. Group sizes unverified.

Results · Original journal abstract. Full PDF tables unavailable.
MeasureResultComparison, timing and statistics
Conditioned swimming avoidanceAcquisition and retention changedThe original abstract gives no numerical effect or group size.
Spontaneous behaviorMore horizontal and vertical movement and less time freezingDirection only from the original abstract. Swimming was an avoidance task.

An animal learning and behavior experiment. Its abstract supplies no athletic endurance endpoint.

Source for these results ↗ · Reviewed 2026-11-09

Population / setting
Laboratory animals in conditioned avoidance and locomotor behavior experiments. Group sizes unverified.
Source reviewed
Original journal abstract. Full PDF tables unavailable.
Study limitations
  • Deltaran contains DSIP and glycine. The contribution of isolated DSIP was not established. Original dose, groups and numerical outcomes remain unverified.

Reviewed 2026-11-09.

Read the source ↗

Animal research · 2017

Deltaran and plasma superoxide dismutase in rats

Plasma superoxide dismutase activity increased 28.6% in male rats and 21.1% in females compared with controls.

Study notes and original source
2017Animal / experimentalFull text available

Deltaran and plasma superoxide dismutase in rats

· Reviews of Clinical Pharmacology and Drug Therapy. 15(Suppl. 2):21–22

Format: Original 2017 Regulatory Neuropeptides conference abstract, pp. 21–22 · Reviewed: Reported methods, results and evidence limitations

S. G. Dagaev, L. G. Kubarskaya, V. A. Kashuro · Reviews of Clinical Pharmacology and Drug Therapy. 15(Suppl. 2):21–22

Plasma superoxide dismutase activity increased 28.6% in male rats and 21.1% in females compared with controls.

Results and tables

Reported findings and study design

Plasma superoxide dismutase activity increased 28.6% in male rats and 21.1% in females compared with controls.

Male and female rats received intranasal Deltaran for five days and were compared with controls. The abstract reports six per group and measures plasma protein, lipids and antioxidant enzyme activity.

Population or model Male and female laboratory rats. The abstract prints n=6 per group.

Protocol information

Intranasal Deltaran for five days. The abstract prints 150 mg/kg for the formulation. The unit and the mass of isolated DSIP are unconfirmed.

Protocol source ↗ · Original 2017 Regulatory Neuropeptides conference abstract, pp. 21–22

Results · Original 2017 Regulatory Neuropeptides conference abstract, pp. 21–22
MeasureResultComparison, timing and statistics
Plasma superoxide dismutase activity+28.6% in males and +21.1% in femalesVersus corresponding controls. · p<0.05 as reported
Plasma protein and total lipidsProtein +14.8% in males and total lipids +20.2% in femalesVersus corresponding controls. The reverse sex-specific comparisons showed no reported difference. · p<0.05 as reported
Female plasma phospholipid share−21.3%Share of plasma lipids, a separate measure from total lipids.

These biomarker changes describe the tested DSIP-plus-glycine formulation.

Source for these results ↗ · Reviewed 2026-11-09

Population / setting
Male and female laboratory rats. The abstract prints n=6 per group.
Source reviewed
Original 2017 Regulatory Neuropeptides conference abstract, pp. 21–22
Study limitations
  • Small conference experiment and an unusually high printed formulation dose. No performance, endurance or human endpoint was measured.

Reviewed 2026-11-09.

Read the source ↗

Animal research · 2006

Age and baseline anxiety in Lysenko’s peptide stress models

The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.

Study notes and original source
2006Animal / experimentalRussian-language source

Age and baseline anxiety in Lysenko’s peptide stress models

· Doctoral dissertation, 244 pp., introduction and conclusions

Format: Author’s abstract transcription. Full dissertation and underlying records unavailable. · Reviewed: Reported methods, results and evidence limitations

A. V. Lysenko · Doctoral dissertation, 244 pp., introduction and conclusions

The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.

Results and tables

Reported findings and study design

The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.

Hypokinesia, hypoxia and exertion models, with behavioral, immune and oxidative endpoints. Twenty-four-hour hypokinesia was one stress protocol.

Population or model Rats grouped by age and baseline anxiety; series-specific denominators remain unverified.

Results · Author’s abstract transcription. Full dissertation and underlying records unavailable.
MeasureResultComparison, timing and statistics
High-anxiety young ratsVilon and GVS-111 were highlighted in the author’s conclusionsOriginal group-level numerical estimates and doses still need retrieval.
Stress-response directionFavorable and unfavorable responses describedThe author discusses this for GVS-111 and an experimental preparation called NKT. NKT identity remains unresolved.

A mechanistic program on stress response. The dissertation-level conclusion does not isolate all preparation-specific effects.

Source for these results ↗ · Reviewed 2026-11-09

Population / setting
Rats grouped by age and baseline anxiety; series-specific denominators remain unverified.
Source reviewed
Author’s abstract transcription. Full dissertation and underlying records unavailable.
Study limitations
  • Potential overlap with narrower author-network dissertations, including Morgul and Rudenko. Outcomes cannot be pooled or assigned to humans.

Reviewed 2026-11-09.

Read the source ↗

Comparison in people · 2008

Ganapolsky climate chambers: Cortexin, Noopept and related comparators

Reported cycling work capacity in healthy men aged 20–24.

Study notes and original source
2008Human comparative studyRussian-language source

Ganapolsky climate chambers: Cortexin, Noopept and related comparators

· Original dissertation author abstract

Format: Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending. · Reviewed: Reported methods, results and evidence limitations

V. P. Ganapolsky · Development and Study of New Meteoadaptogens, Kirov Military Medical Academy doctoral author abstract

In cold, Cortexin participants averaged 210 W versus 162 W with placebo. In heat, Noopept averaged 188 W versus 152 W with placebo.

Results and tables

Reported findings and study design

In cold, Cortexin participants averaged 210 W versus 162 W with placebo. In heat, Noopept averaged 188 W versus 152 W with placebo.

Tabai climatic chamber: −10°C with 2.5 m/s airflow, +45°C at 80% humidity, or 3,000 m simulated altitude. The abstract specifies 40 minutes for cold and heat and 90 minutes at altitude within a longer chamber session.

Population or model 301 men aged 20–24 across the full program. Selected tables compare 17 Cortexin, 18 Noopept, 17 Cerebrolysin and nine placebo participants, with historical controls in cold.

Dose, route and schedule

Intranasal amounts in the author abstract: Cortexin 0.5 mg, Noopept 0.1 mg, Cerebrolysin 43 mg, Dilept 0.1 mg, Semax 0.2 mg and Deltaran 20 mg. Oral Vinpotropil contained piracetam 400 mg and vinpocetine 5 mg. Arms and testing series differ.

Protocol source ↗ · Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending.

Results · Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending.
MeasureResultComparison, timing and statistics
Cortexin · cold (n=17)155 → 210 W vs 159 → 162 W with placeboBefore chamber to during exposure; the 210 W mean is marked p<0.05 versus placebo and historical controls.
Noopept · heat (n=18)182 → 188 W vs 164 → 152 W with placeboBefore chamber to during exposure; the 188 W mean is marked p<0.05 versus placebo.
Cortexin · simulated altitude170 → 170 W vs 162 → 154 W with placebo
Cerebrolysin · heat (n=17)194 → 138 W vs 164 → 152 W with placebo
Dilept · cold (n=16)182 W during exposureThe author reports 12% higher than the historical untreated control.
Semax · cold (n=17)195 → 161 WSeparate comparison. The in-chamber group mean was near control.
Deltaran · cold (n=18)196 → 217 WSeparate comparison. The author reports a significant increase from the pre-chamber measure.
Selected in-chamber PWC₁₇₀ means (W)
Selected in-chamber PWC₁₇₀ means (W)
GroupColdHeatSimulated altitude
Cortexin (n=17)210155170
Noopept (n=18)189188197
Cerebrolysin (n=17)157138152
Placebo (n=9)162152154

PWC₁₇₀ is the cycling workload at 170 beats/min. These are descriptive group means.

The ledger uses the 301-person dissertation total once for these related reports.

Source for these results ↗ · Reviewed 2026-11-17

Population / setting
301 men aged 20–24 across the full program. Selected tables compare 17 Cortexin, 18 Noopept, 17 Cerebrolysin and nine placebo participants, with historical controls in cold.
Source reviewed
Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending.
Study limitations
  • Pre-chamber values reflect the testing protocol and are not established drug-free baselines. Small groups and multiple outcomes limit interpretation.
  • Related 2007 journal and conference reports share investigators, treatments and chamber conditions. Matching workload means indicate overlap.

Reviewed 2026-11-17.

Read the source ↗

Animal research · 2009

Shabanov’s rat peptide behavior comparison: Oleyl-Cortagen and Cortexin

Separate comparisons in an assay battery.

Study notes and original source
2009Animal / experimentalFull text available

Shabanov’s rat peptide behavior comparison: Oleyl-Cortagen and Cortexin

· Original journal article

Format: Publisher full-text methods and results narrative; original PDF tables not recovered · Reviewed: Reported methods, results and evidence limitations

P. D. Shabanov et al. · Medical Academic Journal, 2009; publisher article 9357

Oleyl-Cortagen and Cortexin increased hypothalamic self-stimulation by 32% and 23%, respectively. Cortagen and Cerebrolysin did not change this outcome; other behavioral assays differed.

Results and tables

Reported findings and study design

Oleyl-Cortagen and Cortexin increased hypothalamic self-stimulation by 32% and 23%, respectively. Cortagen and Cerebrolysin did not change this outcome; other behavioral assays differed.

192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery

Population or model 192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery

Dose, route and schedule

Intraperitoneal doses: 1 mg/kg Cortexin, Cerebrolysin, Cortagen, Oleyl-Cortagen, Noopept and Dilept; 0.1 mg/kg Deltaran, Semax and Selank; piracetam 200 mg/kg. General behavior tests 30–40 minutes post-dose; self-stimulation measured 15–20 minutes post-dose.

Protocol source ↗ · Publisher full-text methods and results narrative; original PDF tables not recovered

Results · Publisher full-text methods and results narrative; original PDF tables not recovered
MeasureResultComparison, timing and statistics
Oleyl-Cortagen · self-stimulation+32% in lateral-hypothalamic pedal pressesReported relative increase, not an endurance or strength endpoint.
Cortexin · self-stimulation+23% in lateral-hypothalamic pedal pressesReported relative increase; no direct statistical test versus Oleyl-Cortagen supplied in narrative.
Cortagen and Cerebrolysin · self-stimulationNo change reported in pedal-press frequencyAt the systemic doses in this article; does not contradict the separate central-dose comparisons.
Open-field behaviorOleyl-Cortagen increased horizontal and vertical movement but halved hole explorationCortexin and Cerebrolysin increased horizontal movement; Dilept reduced horizontal and vertical movement.
Noopept, Semax, Selank and Dilept · vertical activityReduced vertical movements reportedCompound-specific rat behavior at the stated doses, not a measure of human alertness.
Porsolt immobilityLower with Oleyl-Cortagen, Dilept and Cortexin; higher with Cerebrolysin, Semax, Cortagen and SelankThis unweighted behavior assay is distinct from loaded endurance swimming. Piracetam was inactive in the report.
Deltaran · groomingGrooming reactions increasedThe report tested Deltaran, a DSIP-containing formulation; this observation is not assigned to isolated DSIP.

Opposing effects across assays are informative. Electrical self-stimulation and immobility are behavior readouts, and neither establishes improved human motivation or endurance.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery
Source reviewed
Publisher full-text methods and results narrative; original PDF tables not recovered
Study limitations
  • Multiple behavioral comparisons, endpoint-specific group sizes and precise uncertainties need table recovery.
  • Deltaran is the tested DSIP-containing formulation; no result for isolated DSIP can be inferred.
  • The 2015 dissertation used separate doses/routes; it is not confirmed as independent replication of every experiment.

Reviewed 2026-11-08.

Read the source ↗

Animal research · 1999

DSIP across hypoxia, swimming, immobilization and audiogenic stress

The author describes brain monoamine changes observed up to five days after a DSIP injection and delayed fatigue in forced swimming.

Monoamine time course · Selected changes observed for up to 5 days after an injection · Measurements of brain neurochemistry; not drug exposure or human duration of action.

Study notes and original source
1999Animal / experimentalRussian-language source

DSIP across hypoxia, swimming, immobilization and audiogenic stress

· Dissertation

Format: Accessible dissertation or author-abstract transcription; full scan and original tables not recovered · Reviewed: Reported methods, results and evidence limitations

D. V. Alperovich · Rostov-on-Don doctoral dissertation, 338 pp.

The author describes brain monoamine changes observed up to five days after a DSIP injection and delayed fatigue in forced swimming.

Results and tables

Reported findings and study design

The author describes brain monoamine changes observed up to five days after a DSIP injection and delayed fatigue in forced swimming.

Animal experiments in multiple stress models; group counts not verified in accessible text

Population or model Animal experiments in multiple stress models; group counts not verified in accessible text

Protocol information

The dissertation excerpt describes a single pretreatment injection in selected series. Exact dose, route and timing by series were not recovered.

Protocol source ↗ · Accessible dissertation or author-abstract transcription; full scan and original tables not recovered

Results · Accessible dissertation or author-abstract transcription; full scan and original tables not recovered
MeasureResultComparison, timing and statistics
Monoamine time courseSelected changes observed for up to 5 days after an injectionMeasurements of brain neurochemistry; not drug exposure or human duration of action.
Forced swimmingLonger time before fatigue describedNo verified numerical swim-time contrast in accessible conclusions.
Other stress modelsChanges in leukocyte pattern, lipid peroxidation and membrane measuresHypoxia, restricted movement and audiogenic stress; distinct experiments.

An archival stress-response hypothesis. Exact effects and dose schedules remain unresolved.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Animal experiments in multiple stress models; group counts not verified in accessible text
Source reviewed
Accessible dissertation or author-abstract transcription; full scan and original tables not recovered
Study limitations
  • Five days refers to observation of selected biochemical changes, not measured half-life or five days of benefit.
  • Swimming time and survival magnitudes and adverse effects require full results tables.

Reviewed 2026-11-08.

Read the source ↗

Animal research · 2004

DSIP analogues ID-1, ID-3 and ID-8 in age-stratified rat stress models

The dissertation describes analogue- and age-dependent changes in leukocytes, oxidative markers and chromosome damage. ID-3 and piracetam were highlighted in older rats.

Study notes and original source
2004Animal / experimentalRussian-language source

DSIP analogues ID-1, ID-3 and ID-8 in age-stratified rat stress models

· Dissertation

Format: Accessible dissertation or author-abstract transcription; full scan and original tables not recovered · Reviewed: Reported methods, results and evidence limitations

E. I. Rakhmanova · Candidate dissertation, 152 pp.; Makhachkala author abstract, 22 pp.

The dissertation describes analogue- and age-dependent changes in leukocytes, oxidative markers and chromosome damage. ID-3 and piracetam were highlighted in older rats.

Results and tables

Reported findings and study design

The dissertation describes analogue- and age-dependent changes in leukocytes, oxidative markers and chromosome damage. ID-3 and piracetam were highlighted in older rats.

Rats of different ages under intact and restricted-movement conditions; DSIP and piracetam served as distinct comparators

Population or model Rats of different ages under intact and restricted-movement conditions; DSIP and piracetam served as distinct comparators

Results · Accessible dissertation or author-abstract transcription; full scan and original tables not recovered
MeasureResultComparison, timing and statistics
Analogue identitiesID-1, ID-3 and ID-8 tested separately from parent DSIP and piracetamAnalogue codes are reported; sequence-level identity was not independently resolved.
Age and oxidative responseID-3 and piracetam were highlighted in old rats, including slower MDA formationQualitative conclusions only; no verified magnitude.
Other endpointsLeukocyte profile and chromosomal-aberration outcomes varied by analogue and ageRestricted-movement model; biochemical and cytogenetic effects rather than sport performance.

The primary value is a lead for analogue-specific research; the parent peptide and analogues remain distinct.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Rats of different ages under intact and restricted-movement conditions; DSIP and piracetam served as distinct comparators
Source reviewed
Accessible dissertation or author-abstract transcription; full scan and original tables not recovered
Study limitations
  • Sequence identities, exact comparative estimates and doses need original table recovery.
  • The activity of these analogues does not establish an effect of DSIP itself or efficacy in humans.

Reviewed 2026-11-08.

Read the source ↗

Animal research · 2014

Pinealon, Cortexin and Deltaran: prenatal-stress conference findings

Deltaran, a DSIP-containing preparation with glycine, had 96% reported offspring survival in the 2014 conference abstract. Group sizes and an untreated-hypoxia survival rate are missing; the biochemical result is internally contradictory.

Study notes and original source
2014Animal / experimentalRussian-language source

Pinealon, Cortexin and Deltaran: prenatal-stress conference findings

Cortexin mixture, Pinealon and Deltaran (DSIP-containing formulation); separate groups · Conference abstract

Format: Original PDF · Reviewed: Original congress proceedings reproduced by an academic repository; printed pp.233–234 visually checked

A. M. Mendzheritskii, G. V. Karantysh · X International Congress “Neuroscience for Medicine and Psychology”, Sudak, 2–12 June 2014, pp.233–234

The abstract reports 96% survival with Deltaran and 94% with Pinealon, without denominators or an untreated-hypoxia survival rate. Learning favored Deltaran then Pinealon then Cortexin, but contradictory caspase-3 statements remain unresolved.

Results and tables

Reported findings and study design

Reported findings

The abstract reports 96% survival with Deltaran and 94% with Pinealon, without denominators or an untreated-hypoxia survival rate. Learning favored Deltaran then Pinealon then Cortexin, but contradictory caspase-3 statements remain unresolved.

Maternal intraperitoneal exposure throughout pregnancy. Daily hypobaric hypoxia on gestation days 13–20, 66.41 kPa for three hours. Offspring Morris maze and cortical/brainstem caspase-3 at day 21.

Population or model 21-day-old outbred rat offspring; seven listed treatment groups; no group sizes supplied

Dose, route and schedule

Maternal doses as printed: Cortexin 1 mg/kg, Pinealon 10 µg/kg, Deltaran 12 µg/100 g body weight; intraperitoneally throughout gestation. The abstract does not resolve whether Deltaran mass means formulation or active peptide. These are historical animal methods.

Protocol source ↗ · Original congress proceedings reproduced by an academic repository; printed pp.233–234 visually checked

Results · Original congress proceedings reproduced by an academic repository; printed pp.233–234 visually checked
MeasureResultComparison, timing and statistics
Reported survivalDeltaran 96%; Pinealon 94%No n, uncertainty, untreated-hypoxia rate or numerical Cortexin survival supplied
Latent learningAuthors rank Cortexin < Pinealon < DeltaranNo group mean latency, variance or between-treatment p-values
Caspase-3 conflictDeltaran+hypoxia is described as +144% in cortex and +109% in brainstem, then as remaining at control levelBoth statements occur in the same abstract; do not resolve by assumption · First sentence: p<0.0001 and p<0.001, respectively
Comparator gapSeven-group list lacks a hypoxia-only untreated armAn omitted group may exist, but it cannot be reconstructed from the abstract

Conference abstract with missing denominators and an internally inconsistent biochemical result; not a clinical trial. Deltaran is a DSIP-containing formulation with glycine; results are not proof for isolated DSIP. Formulation mass versus active-peptide mass is not resolved by this abstract. Shared Rostov authors and models may overlap the 2012 papers and dissertations; no pooled sample or independent-replication count is calculated.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
21-day-old outbred rat offspring; seven listed treatment groups; no group sizes supplied
Source reviewed
Original congress proceedings reproduced by an academic repository; printed pp.233–234 visually checked
Study limitations
  • Conference abstract with missing denominators and an internally inconsistent biochemical result; not a clinical trial.
  • Deltaran is a DSIP-containing formulation with glycine; results are not proof for isolated DSIP. Formulation mass versus active-peptide mass is not resolved by this abstract.
  • Shared Rostov authors and models may overlap the 2012 papers and dissertations; no pooled sample or independent-replication count is calculated.

Reviewed 2026-11-08.

Read the source ↗

Controlled study in people · 1981

Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior

In a double-blind crossover experiment, median total sleep time during the 130-minute post-infusion interval was 59% higher with DSIP than placebo. This was an acute sleep experiment in six healthy volunteers.

Study notes and original source
1981Clinical trial / comparisonEnglish abstract

Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior

· Original journal report

Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA · Int J Clin Pharmacol Ther Toxicol 19:341-345

In a double-blind crossover experiment, median total sleep time during the 130-minute post-infusion interval was 59% higher with DSIP than placebo. This was an acute sleep experiment in six healthy volunteers.

Results and tables

Reported findings and study design

In a double-blind crossover experiment, median total sleep time during the 130-minute post-infusion interval was 59% higher with DSIP than placebo. This was an acute sleep experiment in six healthy volunteers.

Population or model 6 healthy volunteers: 4 men and 2 women.

Dose, route and schedule

Slow morning intravenous DSIP infusion, 25 nmol/kg, versus placebo. Historical study methods, not personal-use instructions.

Protocol source ↗ · Indexed abstract

Results · Indexed abstract
MeasureResultComparison, timing and statistics
Median total sleep time59% higher than placebo130-minute post-infusion interval
Participants6 healthy volunteers

No absolute sleep-duration values or confidence interval are provided in the abstract. A six-person experiment cannot establish long-term insomnia treatment effects.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
6 healthy volunteers: 4 men and 2 women.
Source reviewed
Primary indexed abstract and publication metadata checked through Europe PMC on 1 November 2026. Full-text methods not reviewed.
Study limitations
  • No absolute sleep-duration values or confidence interval are provided in the abstract.
  • A six-person experiment cannot establish long-term insomnia treatment effects.

Reviewed 2026-11-01.

Read the source ↗

Comparison in people · 1993

Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women

DSIP did not change spontaneous or arginine-stimulated growth hormone or prolactin secretion. The placebo-comparison subset comprised three women.

Study notes and original source
1993Human comparative studyEnglish abstract

Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women

· Original journal report

Giusti M, Carraro A, Porcella E, Valenti S, Nicora D, Sessarego P, Giordano G · Psychoneuroendocrinology 18:79-84

DSIP did not change spontaneous or arginine-stimulated growth hormone or prolactin secretion. The placebo-comparison subset comprised three women.

Results and tables

Reported findings and study design

DSIP did not change spontaneous or arginine-stimulated growth hormone or prolactin secretion. The placebo-comparison subset comprised three women.

Population or model 8 healthy women overall; only 3 entered the DSIP-versus-placebo circadian comparison.

Dose, route and schedule

In the three-woman circadian comparison, DSIP 25 micrograms/kg intravenously from 21:30 to 22:30 versus placebo infusion. Historical study methods, not personal-use instructions.

Protocol source ↗ · Indexed abstract

Results · Indexed abstract
MeasureResultComparison, timing and statistics
Growth hormone and prolactinNo change in secretion or circadian rhythm
Placebo-comparison subset3 women8 women participated across all experiments

Five other women underwent arginine challenge conditions; eight is not the placebo-comparison sample size. Randomization and masking are not stated in the abstract.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
8 healthy women overall; only 3 entered the DSIP-versus-placebo circadian comparison.
Source reviewed
Primary indexed abstract and publication metadata checked through Europe PMC on 1 November 2026. Full-text methods not reviewed.
Study limitations
  • Five other women underwent arginine challenge conditions; eight is not the placebo-comparison sample size.
  • Randomization and masking are not stated in the abstract.

Reviewed 2026-11-01.

Read the source ↗

Animal research · 1997

Studies of the mechanism of the anticonvulsant effect of delta-sleep-inducing peptide in conditions of increased oxygen tension.

An intraperitoneal DSIP dose of 12 μg per 100 g body weight delayed generalized convulsions by 2–2.5-fold in a hyperbaric oxygen experiment. This English report may overlap the 1996 Russian publication.

Study notes and original source
1997Animal / experimentalEnglish abstract

Studies of the mechanism of the anticonvulsant effect of delta-sleep-inducing peptide in conditions of increased oxygen tension.

Preparation-specific research; no equivalence inferred

Mendzheritskii AM, Lysenko AV, Uskova NI, Sametskii EA. · Neuroscience and behavioral physiology

An intraperitoneal DSIP dose of 12 μg per 100 g body weight delayed generalized convulsions by 2–2.5-fold in a hyperbaric oxygen experiment. This English report may overlap the 1996 Russian publication.

Results and tables

Reported findings and study design

Investigators varied three DSIP doses and the timing before compression in a chamber to an oxygen tension of 0.7 MPa.

Population or model Animal hyperbaric oxygen experiment. The abstract gives no arm sizes.

Dose, route and schedule

The abstract identifies 12 μg per 100 g (120 μg/kg) intraperitoneally as the most effective dose tested. It does not give the other doses or exact pretreatment intervals.

Protocol source ↗ · Original paper abstract

Results · Original paper abstract
MeasureResultComparison, timing and statistics
Onset of generalized convulsions2–2.5-fold delay with DSIP at 12 μg per 100 gAt 0.7 MPa oxygen tension
Sleep–wake cycleThe investigators reported recovery toward normal cycling within 24 hours after hyperbaric oxygen exposure.

The English paper may correspond to the earlier Russian publication. The experiment concerns oxygen-induced convulsions in animals.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
Animal hyperbaric oxygen experiment. The abstract gives no arm sizes.
Source reviewed
Original paper abstract
Study limitations
  • The abstract leaves the preparation and study methods unclear.
  • Related publications may share experiments; source count is not independent-study count.

Reviewed 2026-11-16.

Read the source ↗

Controlled study in people · 1987

Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.

A 14-person placebo-controlled insomnia report described improved sleep and daytime performance over seven nights of DSIP, without giving numerical sleep or performance effect sizes in its abstract.

Study notes and original source
1987Clinical trial / comparisonEnglish abstract

Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.

Ordinary DSIP

Schneider-Helmert D · European neurology 27(2):120-129

A 14-person placebo-controlled insomnia report described improved sleep and daytime performance over seven nights of DSIP, without giving numerical sleep or performance effect sizes in its abstract.

Results and tables

Reported findings and study design

A 14-person placebo-controlled insomnia report described improved sleep and daytime performance over seven nights of DSIP, without giving numerical sleep or performance effect sizes in its abstract.

14 middle-aged chronic insomniacs; double-blind placebo-controlled administration and polysomnography.

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Sleep and daytime performanceReported improvements; numerical changes not suppliedSleep effects reportedly persisted on the first placebo post-treatment night
Participants14 chronic-insomnia patients
Observation schedule7 successive treatment nights; daytime testing before and after 6 injections

This positive report is shown alongside the separate weak/neutral DSIP comparisons; their findings should not be pooled without full methods.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
14 middle-aged patients with chronic insomnia
Source reviewed
Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
  • Small sample and short follow-up; allocation and complete methods require appraisal.

Reviewed 2026-11-01.

Read the source ↗

Controlled study in people · 1987

Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs.

A double-blind crossover study found little clinically significant sleep improvement with DSIP; some nominal sleep-stage differences were already present at baseline.

Study notes and original source
1987Clinical trial / comparisonEnglish abstract

Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs.

Ordinary DSIP

Monti JM, Debellis J, Alterwain P, Pellejero T, Monti D · International journal of clinical pharmacology research 7(2):105-110

A double-blind crossover study found little clinically significant sleep improvement with DSIP; some nominal sleep-stage differences were already present at baseline.

Results and tables

Reported findings and study design

A double-blind crossover study found little clinically significant sleep improvement with DSIP; some nominal sleep-stage differences were already present at baseline.

Insomnia patients studied over four nights with polysomnography; sample size not stated in the abstract.

Population or model Patients with chronic insomnia; double-blind crossover

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Awakenings and wake timeDecreased during DSIP, without significant baseline or placebo differencesAlso applies to NREM latency and waking after sleep onset
NREM and stage 2 sleepNominal differences versus placebo, with the same differences already present at baseline
Slow-wave and REM sleepNot modified
Studied exposure25 nmol/kg intravenously; four-night crossover

The abstract contains no sleep-duration effect sizes or arm-level counts. Its conclusion is limited clinical significance.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
Patients with chronic insomnia; double-blind crossover
Source reviewed
Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
  • Baseline differences complicate interpretation; sample size is not provided in the indexed abstract.

Reviewed 2026-11-01.

Read the source ↗

Controlled study in people · 1992

Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.

In 16 chronic-insomnia patients, DSIP produced weak objective sleep differences and no consistent subjective sleep benefit; the authors found little likely therapeutic value.

Study notes and original source
1992Clinical trial / comparisonEnglish abstract

Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.

Ordinary DSIP

Bes F, Hofman W, Schuur J, Van Boxtel C · Neuropsychobiology 26(4):193-197

In 16 chronic-insomnia patients, DSIP produced weak objective sleep differences and no consistent subjective sleep benefit; the authors found little likely therapeutic value.

Results and tables

Reported findings and study design

In 16 chronic-insomnia patients, DSIP produced weak objective sleep differences and no consistent subjective sleep benefit; the authors found little likely therapeutic value.

Double-blind matched-pairs parallel comparison: 8 DSIP, 8 glucose placebo; five laboratory nights.

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Objective sleepHigher efficiency and shorter latency, described as weak effectsAuthors note possible contribution from incidental placebo-group changes
Subjective sleep qualityNo changeNo numerical sleep-minute difference in the abstract
Participants8 DSIP; 8 placebo
Studied schedule25 nmol/kg IV before nights 3, 4 and 5

Design figures are available; objective effect sizes in minutes and confidence intervals are not. The original authors did not infer a major therapeutic benefit.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
16 patients; double-blind matched-pairs parallel groups
Source reviewed
Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
  • Small, brief study; selected statistically significant endpoints do not establish a meaningful overall benefit.

Reviewed 2026-11-01.

Read the source ↗

Animal research · 1995

[Ratio of neuromediator amino acids in a comparative analysis of the stress protective effects of delta-sleep inducing peptide and piracetam].

Combined DSIP and piracetam administration was associated with stronger stress-related effects on the balance of inhibitory and excitatory amino acids than individual compounds.

Study notes and original source
1995Animal / experimentalEnglish abstract

[Ratio of neuromediator amino acids in a comparative analysis of the stress protective effects of delta-sleep inducing peptide and piracetam].

DSIP + piracetam

Mendzheritskiĭ AM, Uskova NI, Lysenko AV, Matsionis AE, Sametskiĭ EA · Voprosy meditsinskoi khimii 41(5):16-19

Combined DSIP and piracetam administration was associated with stronger stress-related effects on the balance of inhibitory and excitatory amino acids than individual compounds.

Population / setting
Rats exposed to one-hour restricted movement
Source reviewed
Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
  • Biochemical animal endpoints; no evidence of human cognitive or occupational benefit. Full data are needed to assess additivity versus synergy.

Reviewed 2026-10-01.

Read the source ↗

Animal research · 1999

Metabolic features of the adaptive effect of delta-sleep inducing peptide and piracetam under hyperoxic conditions.

The combination enhanced reported protection alongside changes in neurotransmitter amino acids, membrane ATPase activity and lipid-peroxidation products.

Study notes and original source
1999Animal / experimentalEnglish abstract

Metabolic features of the adaptive effect of delta-sleep inducing peptide and piracetam under hyperoxic conditions.

Author affiliations · Neurocybernetics Institute, Rostov State University

DSIP + piracetam

Lysenko AV, Alperovich DV, Uskova NI, Mendzheritsky AM · Biochemistry. Biokhimiia 64(6):652-657

The combination enhanced reported protection alongside changes in neurotransmitter amino acids, membrane ATPase activity and lipid-peroxidation products.

Results and tables

Reported findings and study design

Rat cortical-membrane experiment: single IP DSIP 12 micrograms/100 g and IP piracetam 3 mg/100 g/day for three days; hyperbaric oxygen 0.3 MPa for two hours.

Population or model Rats exposed to hyperbaric oxygen at 0.3 MPa for two hours

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Combination responseGreater protection than individual treatments reportedNo numerical biochemical effect size supplied

Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
Rats exposed to hyperbaric oxygen at 0.3 MPa for two hours
Source reviewed
Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
  • Hyperoxia is excess oxygen, not oxygen deprivation. These animal findings do not establish a human diving, sleep or performance regimen.

Reviewed 2026-10-01.

Read the source ↗

Animal research · 1995

[Proteolytic processes in the rat brain and serum in hypokinesia and the adaptive effect of delta-sleep inducing peptide].

DSIP changed proteolytic enzyme activity and was reported to prevent lysosomal-membrane permeability disturbances during prolonged restricted movement.

Study notes and original source
1995Animal / experimentalEnglish abstract

[Proteolytic processes in the rat brain and serum in hypokinesia and the adaptive effect of delta-sleep inducing peptide].

Ordinary DSIP

Mendzheritskiĭ AM, Lysenko AV, Uskova NI · Biokhimiia (Moscow, Russia) 60(4):585-592

DSIP changed proteolytic enzyme activity and was reported to prevent lysosomal-membrane permeability disturbances during prolonged restricted movement.

Population / setting
Rat brain and serum under hypokinesia
Source reviewed
Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
  • Proposed preadaptation through regulatory-peptide metabolism is a mechanistic interpretation, not a demonstrated human effect.

Reviewed 2026-10-01.

Read the source ↗

Animal research · 1996

[The mechanism of the anticonvulsive effect of the delta sleep-inducing peptide under conditions of elevated oxygen pressure].

The authors reported seizure protection accompanied by higher cortical GABA and homocarnosine and lower glutamate and aspartate.

Study notes and original source
1996Animal / experimentalEnglish abstract

[The mechanism of the anticonvulsive effect of the delta sleep-inducing peptide under conditions of elevated oxygen pressure].

Ordinary DSIP

Mendzheritskiĭ AM, Lysenko AV, Uskova NI, Sametskiĭ EA · Fiziologicheskii zhurnal imeni I.M. Sechenova 82(1):59-64

The authors reported seizure protection accompanied by higher cortical GABA and homocarnosine and lower glutamate and aspartate.

Population / setting
Rats under elevated oxygen pressure
Source reviewed
Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
  • Oxygen-toxicity model; not evidence for treating human epilepsy or oxygen deprivation.

Reviewed 2026-10-01.

Read the source ↗

Animal research · 1986

[Active analog of the inactive "sleep peptide"].

The D-Trp¹ analogue increased slow-wave sleep under the reported conditions; central administration also raised body temperature.

Rectal temperature · 0.9 °C increase · p<0.01

Study notes and original source
1986Animal / experimentalEnglish abstract

[Active analog of the inactive "sleep peptide"].

D-Trp¹-DSIP analogue

Koval'zon VM, Kalikhevich VN, Churkina SI · Biulleten' eksperimental'noi biologii i meditsiny 101(6):707-709

The D-Trp¹ analogue increased slow-wave sleep under the reported conditions; central administration also raised body temperature.

Results and tables

Reported findings and study design

Rabbit study of the modified (D-Trp¹)DSIP analogue, not parent DSIP; central doses 0.7, 7 or 70 micrograms/kg.

Population or model Rabbits; central and intravenous analogue administration

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Slow-wave sleep after central administration40% increase over three daylight hoursp<0.01
Rectal temperature0.9 °C increasep<0.01
Slow-wave sleep after IV analogue25% increase at 30–70 micrograms/kg

The positive figures belong to the D-Trp analogue; parent DSIP’s sleep-inducing properties were not demonstrated in this report.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
Rabbits; central and intravenous analogue administration
Source reviewed
Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
  • Modified peptide, not ordinary DSIP. Route, narrow effective range and species constrain extrapolation.

Reviewed 2026-10-01.

Read the source ↗

Animal research · 1986

Structure-activity relationship in the effects of delta-sleep-inducing peptide (DSIP) on rat sleep.

Ordinary DSIP did not increase sleep. D-Trp¹ and D-Tyr¹ analogues promoted sleep, while a shortened D-Trp¹ fragment produced arousal.

Study notes and original source
1986Animal / experimentalEnglish abstract

Structure-activity relationship in the effects of delta-sleep-inducing peptide (DSIP) on rat sleep.

DSIP and modified analogues

Obál F Jr, Kovalzon VM, Kalikhevich VN, Török A, Alföldi P, Sáry G, Hajós M, Penke B · Pharmacology, biochemistry, and behavior 24(4):889-894

Ordinary DSIP did not increase sleep. D-Trp¹ and D-Tyr¹ analogues promoted sleep, while a shortened D-Trp¹ fragment produced arousal.

Population / setting
Rats; intracerebroventricular administration
Source reviewed
Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
  • Structure and experimental timing matter. Central animal administration cannot be transferred to commercial DSIP products.

Reviewed 2026-10-01.

Read the source ↗

Animal research · 1986

[Peptidergic modulation of sleep: a comparative study of analogs of the peptide DSIP].

Full-length modified analogues increased sleep; the shortened fragment reduced slow-wave sleep in rats but had no effect in rabbits.

Study notes and original source
1986Animal / experimentalEnglish abstract

[Peptidergic modulation of sleep: a comparative study of analogs of the peptide DSIP].

DSIP analogues

Koval'zon VM, Obál F Jr, Kalikhevich VN · Zhurnal evoliutsionnoi biokhimii i fiziologii 22(5):483-488

Full-length modified analogues increased sleep; the shortened fragment reduced slow-wave sleep in rats but had no effect in rabbits.

Population / setting
Rabbits and rats; implanted electrodes and cannulas
Source reviewed
Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
  • Potential overlap with related 1986 experiments needs full-text comparison; not automatically independent replication.

Reviewed 2026-10-01.

Read the source ↗

Animal research · 2001

[Hypnogenic properties of DSIP peptide analogs: structural-functional relationship].

Ordinary DSIP and most analogues had no significant effect. N-MeAla² and Pro² analogues increased slow-wave sleep, whereas β-Ala² suppressed it.

Study notes and original source
2001Animal / experimentalEnglish abstract

[Hypnogenic properties of DSIP peptide analogs: structural-functional relationship].

Author affiliations · Severtsov Institute of Ecology and Evolution, Russian Academy of Sciences

DSIP and 13 analogues

Koval'zon VM · Izvestiia Akademii nauk. Seriia biologicheskaia (4):467-474

Ordinary DSIP and most analogues had no significant effect. N-MeAla² and Pro² analogues increased slow-wave sleep, whereas β-Ala² suppressed it.

Results and tables

Reported findings and study design

Rabbits with implanted electrodes; parent DSIP and 13 analogues administered into the lateral ventricle; daytime recording 7–12 hours.

Population or model Rabbits; DSIP and 13 synthetic analogues

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Parent DSIP and most analoguesNo significant sleep change
[NMeAla²]DSIP and [Pro²]DSIPSlow-wave sleep proportion increased about 10–15%
[β-Ala²]DSIPSleep suppressed

Analogue-specific effects must not be assigned to parent DSIP.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
Rabbits; DSIP and 13 synthetic analogues
Source reviewed
Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
  • Intracerebroventricular animal experiment. The English translation is the same publication, not another study.

Reviewed 2026-10-01.

Read the source ↗

Animal research · 1977

Characterization of a delta-electroencephalogram (-sleep)-inducing peptide.

The Basel group characterized the nine-amino-acid sequence and reported delta/spindle EEG enhancement with synthetic DSIP in its assay.

Study notes and original source
1977Animal / experimentalEnglish abstract

Characterization of a delta-electroencephalogram (-sleep)-inducing peptide.

Synthetic DSIP and comparison peptides

Schoenenberger GA, Monnier M · Proceedings of the National Academy of Sciences of the United States of America 74(3):1282-1286

The Basel group characterized the nine-amino-acid sequence and reported delta/spindle EEG enhancement with synthetic DSIP in its assay.

Population / setting
58 rabbits including controls; peptide characterization
Source reviewed
Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
  • Historical rabbit assay, not clinical validation. Later studies produced inconsistent sleep findings.

Reviewed 2026-10-01.

Read the source ↗

Observational study · 1983

Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors.

An uncontrolled withdrawal report described improvement in 48 of 49 evaluable patients after DSIP, but 18 of 67 enrolled patients were not evaluable.

Study notes and original source
1983Uncontrolled human reportEnglish abstract

Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors.

Ordinary DSIP

Dick P, Grandjean ME, Tissot R · Neuropsychobiology 10(4):205-208

An uncontrolled withdrawal report described improvement in 48 of 49 evaluable patients after DSIP, but 18 of 67 enrolled patients were not evaluable.

Results and tables

Reported findings and study design

An uncontrolled withdrawal report described improvement in 48 of 49 evaluable patients after DSIP, but 18 of 67 enrolled patients were not evaluable.

67 patients with withdrawal symptoms: alcohol 28, opiates 39; DSIP was the sole reported treatment.

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Reported beneficial response48/49 evaluable22 alcohol-withdrawal patients and 26/27 opiate-withdrawal patients
Attrition18/67 not evaluable; abstract reports 27%49 patients contributed to the response analysis
Major adverse effectsNone reportedLimited uncontrolled clinical series
Studied regimen25 nmol/kg intravenously

The evaluable-patient response excludes substantial attrition and has no placebo comparator. It does not establish a safe or effective withdrawal treatment.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
67 withdrawal patients enrolled; 49 evaluable
Source reviewed
Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
  • No control group and substantial exclusion/loss prevent causal conclusions. Not a basis for self-treatment of withdrawal.

Reviewed 2026-11-01.

Read the source ↗

Review of earlier studies · 1986

Delta-sleep-inducing peptide (DSIP): an update.

Reviews sleep and non-sleep research, including pain, withdrawal and DSIP-like material. Physiological roles and mechanisms were unresolved.

Study notes and original source
1986ReviewEnglish abstract

Delta-sleep-inducing peptide (DSIP): an update.

DSIP literature

Graf MV, Kastin AJ · Peptides 7(6):1165-1187

Reviews sleep and non-sleep research, including pain, withdrawal and DSIP-like material. Physiological roles and mechanisms were unresolved.

Population / setting
Historical animal and human literature
Source reviewed
Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
  • Historical synthesis, not a new clinical cohort or current comprehensive safety review.

Reviewed 2026-10-01.

Read the source ↗

Review of earlier studies · 2006

Delta sleep-inducing peptide (DSIP): a still unresolved riddle.

The authors questioned the identity and physiological role of endogenous DSIP and distinguished the parent peptide from active analogues and DSIP-like immunoreactivity.

Study notes and original source
2006ReviewEnglish abstract

Delta sleep-inducing peptide (DSIP): a still unresolved riddle.

Author affiliations · Severtsov Institute of Ecology and Evolution, Russian Academy of Sciences

DSIP, analogues and DSIP-like material

Kovalzon VM, Strekalova TV · Journal of neurochemistry 97(2):303-309

The authors questioned the identity and physiological role of endogenous DSIP and distinguished the parent peptide from active analogues and DSIP-like immunoreactivity.

Population / setting
Critical historical and experimental synthesis
Source reviewed
Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
  • This is the authors’ 2006 assessment, not a claim that a modern exhaustive receptor or gene search has been completed.

Reviewed 2026-10-01.

Read the source ↗

Explore related historical combinations ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗